{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:57:14Z","timestamp":1794862634568,"version":"4.9.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nanoliposomal irinotecan (nal-IRI) was recently authorized in Japan for unresectable pancreatic cancer after disease progression following chemotherapy. Physicians now consider certain aspects of nal-IRI safety profile as slightly different from conventional irinotecan. This report aims to explore additional aspects of the nal-IRI safety in Japanese phase 2 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed the incidence, time to first onset, and time to resolution for adverse events that require special attention and other selected toxicities in the nal-IRI combination group (n\u00a0=\u00a046).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Leukopenia\/neutropenia (76.1%\/71.7%), diarrhea (58.7%) and hepatic dysfunction (41.3%) were the most commonly reported treatment-emergent adverse events, with a median time to onset of 21.0\u00a0days (range: 8, 97), 9.0\u00a0days (1, 61) and 22.0\u00a0days (2, 325), respectively, and a median time to resolution of 8.0\u00a0days (95% confidence intervals: 8, 9), 4.0\u00a0days (4, 8) and 40.0\u00a0days (9, \u2013), respectively. Eight patients experienced Grade\u00a0\u2265\u00a03 diarrhea and their symptoms were well controlled by dose modification except one patient who had drug withdrawal. The median time to resolution for Grade\u00a0\u2265\u00a03 and Grade\u00a0\u2264\u00a02 diarrhea was 17.5\u00a0days (95% confidence intervals: 1, 31) and 4\u00a0days (3, 7), respectively. Anorexia occurred in 28\/46 patients (60.9%) with a median time to onset of 4.0\u00a0days (range: 2, 132) and a median time to resolution of 12.0\u00a0days (95% confidence intervals: 6, 26).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We explored safety profile of nal-IRI combination regimen recognized as effective and tolerable treatment for Japanese unresectable pancreatic cancer patients. Although the treatment-emergent adverse events occurred were controllable, patients with prolonged toxicities should be closely managed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyac177","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T09:53:30Z","timestamp":1668160410000},"page":"130-137","source":"Crossref","is-referenced-by-count":6,"title":["Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial"],"prefix":"10.1093","volume":"53","author":[{"given":"Junji","family":"Furuse","sequence":"first","affiliation":[{"name":"Kanagawa Cancer Center Department of Gastroenterology, , Yokohama, Japan"},{"name":"Kyorin University Faculty of Medicine Department of Medical Oncology, , Mitaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[{"name":"Kanagawa Cancer Center Department of Gastroenterology, , Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East Department of Hepatobiliary & Pancreatic Oncology, , Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Hepatobiliary and Pancreatic Oncology, , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Teng","sequence":"additional","affiliation":[{"name":"Servier Pharmaceuticals Biometrics Department, , Boston MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Furuya","sequence":"additional","affiliation":[{"name":"Nihon Servier CO., LTD Medical Affairs Department, ., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0197-1832","authenticated-orcid":false,"given":"Tatsuya","family":"Ioka","sequence":"additional","affiliation":[{"name":"Yamaguchi University Hospital Oncology Center, , Ube, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"2023013012213089100_ref1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"2023013012213089100_ref2","first-page":"1680","article-title":"International comparison of trends in cancer mortality: Japan has fallen behind in screening-related cancers","volume":"51","author":"Katanoda","year":"2021","journal-title":"Jpn J Clin"},{"key":"2023013012213089100_ref3","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023013012213089100_ref4","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1200\/JCO.20.03329","article-title":"Randomized Phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial","volume":"39","author":"Dahan","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023013012213089100_ref5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.2005.06.050","article-title":"Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study","volume":"23","author":"Conroy","year":"2005","journal-title":"J Clin Oncol"},{"key":"2023013012213089100_ref6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.coc.0000235997.18657.a6","article-title":"FOLFOX-6 combination as the first-line treatment of locally advanced and\/or metastatic pancreatic cancer","volume":"30","author":"Ghosn","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"2023013012213089100_ref7","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2023013012213089100_ref8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","article-title":"A phase II study of modified FOLFIRINOX for chemotherapy-na\u00efve patients with metastatic pancreatic cancer","volume":"81","author":"Ozaka","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023013012213089100_ref9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.6004\/jnccn.2012.0073","article-title":"Pancreatic adenocarcinoma. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines","volume":"10","author":"Tempero","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"2023013012213089100_ref10","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"key":"2023013012213089100_ref11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/MPA.0000000000000816","article-title":"Clinical practice guidelines for pancreatic Cancer 2016 from the Japan Pancreas Society: a synopsis","volume":"46","author":"Yamaguchi","year":"2017","journal-title":"Pancreas"},{"key":"2023013012213089100_ref12","first-page":"iv157","article-title":"Cancer of the pancreas: MCBS eUpdate","volume":"28","author":"ESMO Guidelines Committee","year":"2017","journal-title":"Ann Oncol"},{"key":"2023013012213089100_ref13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/MPA.0000000000001513","article-title":"Clinical practice guidelines for pancreatic Cancer 2019 from the Japan Pancreas Society: a synopsis","volume":"49","author":"Okusaka","year":"2020","journal-title":"Pancreas"},{"key":"2023013012213089100_ref14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"2023013012213089100_ref15","doi-asserted-by":"crossref","first-page":"9396","DOI":"10.1002\/cam4.3558","article-title":"nal-IRI+5-FU\/LV versus 5-FU\/LV in post-gemcitabine metastatic pancreatic cancer: randomized phase 2 trial in Japanese patients","volume":"9","author":"Ueno","year":"2020","journal-title":"Cancer Med"},{"key":"2023013012213089100_ref16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cpt.720","article-title":"Population pharmacokinetics of liposomal irinotecan in patients with cancer","volume":"102","author":"Adiwijaya","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2023013012213089100_ref17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00535-020-01666-y","article-title":"Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines","volume":"55","author":"Okusaka","year":"2020","journal-title":"J Gastroenterol"},{"key":"2023013012213089100_ref18","article-title":"PMDA review report","author":"PMDA Review Report"},{"key":"2023013012213089100_ref19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2018.09.010","article-title":"Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: expanded analysis of a global phase 3 trial","volume":"105","author":"Chen","year":"2018","journal-title":"Eur J Cancer"},{"key":"2023013012213089100_ref20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1186\/s12885-018-4605-1","article-title":"Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience","volume":"18","author":"Glassman","year":"2018","journal-title":"BMC Cancer"},{"key":"2023013012213089100_ref21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2217\/fon-2020-0902","article-title":"Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma","volume":"17","author":"Kim","year":"2021","journal-title":"Future Oncol"},{"key":"2023013012213089100_ref22"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/2\/130\/48945718\/hyac177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/2\/130\/48945718\/hyac177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T07:22:14Z","timestamp":1675063334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/2\/130\/6835388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,21]]},"published-print":{"date-parts":[[2023,1,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac177","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2]]},"published":{"date-parts":[[2022,11,21]]}}}